URO-Y-2: Evaluating Ureteral Length Using Computed Tomography (CT)
Study Details
Study Description
Brief Summary
Proper selection of ureteral stent length might help in reducing comorbidities associated with ureteral stenting, currently there is no standardized way of measuring ureteral length.
Measurement of ureteral length according to Computed Tomography (CT) scan might provide useful information when selecting the length of a ureteral stent. Our aim in this study is to compare ureteral measurements using CT scan and measurement of actual ureteral length measured during ureteral stenting.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Ureteral catheterization During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length. Measurement results will be compared to measurements performed on CT scan (obtained before surgery). |
Device: Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR
During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.
Measurement results will be compared to measurements performed on CT scan (obtained before surgery).
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Agreement between measurement of ureteral length (Centimeters) measured by CT and by ureteral catheterization [1 year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients undergoing planned procedure involving ureteroscopy or ureteral stenting
-
Abdominal CT scan performed within 6 months prior to intervention
Exclusion Criteria:
-
Known iodine sensitivity
-
Patients with fever or hemodynamic instability planned for urgent operation
-
Severe immune compromized patients
-
Severe thrombocytopenia < 50,000
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Carmel Medical Center | Haifa | Israel | 34362 |
Sponsors and Collaborators
- Carmel Medical Center
Investigators
- Principal Investigator: Yuval Freifeld, Dr., Carmel Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CMC-11-0051-CTIL